Side-by-side facts
Vaginal Yeast Infection Treatments: Miconazole vs Clotrimazole vs Tioconazole
Evidence-based comparison of common intravaginal azole treatments by active ingredient, format, course length and key safety boundaries.
Key differences
For a familiar uncomplicated vaginal yeast infection, miconazole, clotrimazole and tioconazole are all established intravaginal azole options; the practical differences are formulation and course length, not a simple strongest-to-weakest ranking. Pregnancy, recurrence, severe symptoms, treatment failure or diagnostic uncertainty change the decision and warrant a different pathway.
| Product | Relevant for | Research status | Main tradeoff | Last checked |
|---|
Compare the treatment formats
| Active ingredient | Example format | Typical labeled course represented here | Evidence position | Key tradeoff |
|---|---|---|---|---|
| Miconazole | 2% vaginal cream | 7 nights | CDC-listed intravaginal azole | Longer course; formulation differs from suppositories and shorter-course miconazole products |
| Clotrimazole | 1% vaginal cream | 7 nights | CDC-listed intravaginal azole | Cream format; repeated nightly application |
| Tioconazole | 6.5% vaginal ointment | Single dose | CDC-listed intravaginal azole | Convenience, but one-dose treatment is not the preferred pattern for every clinical situation |
The useful comparison is not “strongest” or “fastest.” It is active ingredient + route + formulation + course + whether the symptoms fit uncomplicated VVC.
For a broader product-by-product shopping view, see the existing OTC vaginal antifungal regimen comparison.
When the comparison stops being enough
Recurrent symptoms, severe disease, non-albicans Candida, treatment failure, pregnancy, diabetes or immune suppression change the decision. CDC recommends testing or clinician evaluation in several of these situations rather than repeatedly switching OTC products.
During pregnancy, CDC recommends a 7-day topical azole regimen rather than oral fluconazole. That makes course length clinically relevant rather than merely a convenience preference.
See Vaginal yeast infection for diagnosis and recurrence guidance, and Candida & candidiasis for the wider evidence hierarchy.
Primary references
- CDC STI Treatment Guidelines, Vulvovaginal Candidiasis: https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm
- Official DailyMed labels for the compared formulations.
Source trail
Primary documents and supporting evidence
- Vulvovaginal Candidiasis - STI Treatment GuidelinesCenters for Disease Control and Prevention · Clinical guideline · retrieved 2026-08-11
- MICONAZOLE 7 - miconazole nitrate vaginal suppository 100 mgDailyMed, U.S. National Library of Medicine · Regulatory · retrieved 2026-08-11
- Clotrimazole Vaginal Cream USP 1%DailyMed, U.S. National Library of Medicine · Regulatory · retrieved 2026-08-11
- Tioconazole Ointment 6.5%DailyMed, U.S. National Library of Medicine · Regulatory · retrieved 2026-08-11